Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Standard BioTools Inc. (NASDAQ: LAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Forms 10-K, 10-Q and 8-K. These documents offer detailed information about its analytical laboratory instrument manufacturing business, which focuses on SomaScan, mass cytometry and microfluidics technologies used in proteomics and genomics research.
Current reports on Form 8-K are particularly important for tracking material events at Standard BioTools. Recent 8-K filings describe quarterly financial results, including revenue from continuing operations and segment performance, as well as operational restructuring plans involving reductions in force and the consolidation of South San Francisco-based R&D into the company’s Singapore facility. Other 8-Ks detail governance and compensation matters, such as changes to equity incentive plans and retention awards for senior executives.
A key filing for LAB is the Form 8-K describing the Stock Purchase Agreement with Illumina, Inc., under which Illumina will acquire SomaLogic, Inc. and related entities that operate Standard BioTools’ aptamer-based and functional proteomics business. This filing outlines the transaction structure, cash consideration, potential earnouts and royalty arrangements, and the fact that the company’s mass cytometry and microfluidics businesses are being retained.
On Stock Titan, these SEC filings are updated from EDGAR and paired with AI-powered summaries that highlight the main points, such as changes in revenue outlook, restructuring costs, or the terms of significant transactions. Users can quickly identify items related to results of operations, exit or disposal activities, and material definitive agreements, and then drill into the full text of each filing for deeper analysis of LAB’s financial condition, strategic direction and corporate governance.
STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported equity compensation activity and related tax withholding transactions. On April 6, 2026, 196,513 restricted stock units converted into the same number of common shares, and 95,014 of those shares were withheld at $0.908 per share to cover tax obligations. Following these events, he directly held 6,695,582 common shares. On March 20, 2026, he also received a grant of 2,345,340 stock options with a $0.9846 exercise price, expiring in 2036, and a separate award of 1,042,373 shares of common stock; both vest in installments over four years.
STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received new equity awards as part of his compensation. He was granted options to buy 612,240 shares of common stock at an exercise price of $0.9846 per share, expiring on March 20, 2036. These options vest over four years, with 1/16 of the underlying shares vesting on May 20, 2026 and the rest in equal quarterly installments, contingent on continued service. He also received 272,107 restricted stock units that follow the same four‑year vesting schedule, each RSU converting into one share of common stock upon vesting. Following the stock grant, his directly held common stock position is 1,032,281 shares.
STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported routine equity compensation activity and related tax withholding. On March 20, 2026, he received 323,173 shares of common stock and a stock option for 727,140 shares at an exercise price of $0.9846, vesting quarterly after May 20, 2026.
On April 6, 2026, 70,183 restricted stock units converted into the same number of common shares. Of these, 21,301 shares were withheld to cover tax obligations from a prior RSU grant, not sold in the market. After these transactions, he directly held 2,779,401 common shares.
Standard BioTools Inc. files its annual report describing a life sciences tools business focused on proteomics and genomics platforms, including CyTOF, Hyperion and Biomark systems. The company sold its SomaScan proteomics subsidiaries to Illumina under a Stock Purchase Agreement signed June 22, 2025, with the transaction closing January 30, 2026, and now reports those operations as discontinued.
For 2025, it highlights a more than $70 billion addressable market in life science research tools and notes that $56.9 million, or 67% of total revenue, came from customers outside the United States. Standard BioTools reports a 2025 net loss of $74.9 million and an accumulated deficit of $1.3 billion as of December 31, 2025, while emphasizing ongoing restructuring and cost actions.
The company details competitive dynamics against major life science tool providers, dependence on key suppliers, extensive global regulatory and data-privacy obligations, and numerous risk factors ranging from market volatility and acquisitions to litigation related to its merger with SomaLogic. As of March 12, 2026, it had 390,071,506 common shares outstanding, 389 employees worldwide, and a non‑affiliate equity market value of approximately $290.9 million as of June 30, 2025.
Casdin Eli reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director and 10% owner Eli Casdin received 52,991 restricted stock units on the company’s common stock at $1.17 per share equivalent. The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service. Casdin elected to receive these RSUs instead of $62,000 in cash compensation for board work. After this grant, he directly holds 2,954,053 common shares or equivalents, and investment funds associated with him hold additional indirect positions through Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund, L.P., and Casdin Partners Master Fund, L.P.
Cox Troy reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director Troy Cox reported an award of 57,264 restricted stock units representing common stock on February 26, 2026. These RSUs were valued at $1.17 per share for reporting purposes and bring his directly held stake to 376,586 shares after the grant.
The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service through each vesting date. Cox elected to receive this equity grant instead of $67,000 in cash compensation for his board role.
Carey Thomas D. reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director Thomas D. Carey received a grant of 51,282 shares of common stock in the form of restricted stock units valued at $1.17 per share. These RSUs were taken in lieu of $60,000 in cash board compensation and will vest in four equal quarterly installments during 2026, subject to his continued service. Following this grant, his directly held common stock totals 245,340 shares.
STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a Form 4 showing a tax-related share disposition. On the transaction date, 66,127 shares of common stock were withheld at $1.15 per share to cover tax withholding obligations from vesting restricted stock units. After this tax-withholding disposition, Egholm directly owned 5,551,710 shares of common stock.
STANDARD BIOTOOLS INC. executive Sean Mackay, SVP & Chief Business Officer, reported a tax-related share disposition. On February 23, 2026, 19,661 shares of common stock were withheld at $1.15 per share to cover tax obligations from previously granted restricted stock units that vested. After this withholding, Mackay directly holds 760,174 shares of Standard BioTools common stock. This was a tax-withholding disposition, not an open-market purchase or sale.
STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 12,740 shares of common stock at $1.15 per share to cover tax obligations. After this withholding, Kim directly owns 2,407,346 common shares, which includes 5,000 shares acquired on November 28, 2025 under the employee stock purchase plan.